Finland · Delayed Price · Currency is EUR Nexstim Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 16% year-over-year in H1 2026, driven by research and neuroscience, with recurring revenue at 48% of sales and gross margin at 80%. Strategic partnerships and a record order backlog support a positive outlook for H2 2026.
Fiscal Year 2025
-
Revenue grew 26% to EUR 11m in 2025, with record system sales and high gross margins. Strategic partnerships and new product launches drove growth, while recurring revenue saw a temporary dip due to customer purchasing shifts.
-
The company leverages proprietary TMS technology for brain diagnostics and therapy, achieving strong sales growth, high margins, and profitability. Strategic partnerships and international expansion, especially in Asia, are key growth drivers, while long sales cycles and hospital budget constraints remain challenges.
-
Revenue grew 42% in H1 2025, led by diagnostics and new partnerships, with positive EBITDA and strong gross margins. Outlook for 2025 remains positive, supported by the launch of the modular NBS 6 system and continued expansion in diagnostics, therapy, and research.
Fiscal Year 2024
-
Net sales grew 21% to EUR 8.7 million in 2024, with therapy business up 42% and EBITDA positive for the first time. Strategic partnerships with Brainlab and Sinaptica, plus the upcoming NBS 6 diagnostic launch, support a positive 2025 outlook.
-
H1 2024 delivered 27% net sales growth, improved profitability, and strong recurring revenue, with both diagnostic and therapy segments contributing equally. Strategic partnerships and new product launches support a positive outlook for the full year.